Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;123(9):892-903.
doi: 10.1055/s-0043-57017. Epub 2023 Apr 19.

Platelet-Released Extracellular Vesicle Characteristics Differ in Chronic and in Acute Heart Disease

Alba Vilella-Figuerola  1   2 , Alberto Cordero  3   4   5 , Sònia Mirabet  5   6 , Natàlia Muñoz-García  1 , Rosa Suades  1 , Teresa Padró  1   5 , Lina Badimon  1   5   7
Affiliations

Platelet-Released Extracellular Vesicle Characteristics Differ in Chronic and in Acute Heart Disease

Alba Vilella-Figuerola et al. Thromb Haemost. 2023 Sep.

Abstract

Background: Extracellular vesicles (EVs), shed in response to cell activation, stress, or injury, are increased in the blood of patients with cardiovascular disease. EVs are characterized by expressing parental-cell antigens, allowing the determination of their cellular origin. Platelet-derived EVs (pEVs) are the most abundant in blood. Although not universally given, EVs generally express phosphatidylserine (PS) in their membrane.

Objectives: To investigate pEVs in chronic and acute conditions, such as chronic heart failure (CHF) and first-onset acute coronary syndrome (ACS), in patients treated as per guidelines.

Methods: EVs in CHF patients (n = 119), ACS patients (n = 58), their respective controls (non-CHF [n = 21] and non-ACS [n = 24], respectively), and a reference control group (n = 31) were characterized and quantified by flow cytometry, using monoclonal antibodies against platelet antigens, and annexin V (AV) to determine PS exposure.

Results: CHF patients had higher EVs-PS- numbers, while ACS had predominantly EVs-PS+. In contrast to ACS, CHF patients had significantly reduced numbers of pEVs carrying PECAM and αIIb-integrin epitopes (CD31+/AV+, CD41a+/AV+, and CD31+/CD41a+/AV+), while no differences were observed in P-selectin-rich pEVs (CD62P+/AV+) compared with controls. Additionally, background etiology of CHF (ischemic vs. nonischemic) or ACS type (ST-elevation myocardial infarction [STEMI] vs. non-STEMI [NSTEMI]) did not affect pEV levels.

Conclusion: PS exposure in EV and pEV-release differ between CHF and ACS patients, with tentatively different functional capacities beyond coagulation to inflammation and cross-talk with other cell types.

PubMed Disclaimer

Conflict of interest statement

L.B. declares to have acted as a SAB member of Sanofi, Novartis, Ionnis, and Pfizer, to have a Research Grant of AstraZeneca, to have received speaker fees of Sanofi, Novartis, and Bayer, and to have founded the Spin-offs Glycardial Diagnostics SL and Ivastatin Therapeutics S (all unrelated to this work). T.P. declares to be a co-founder of the Spin-offs Glycardial Diagnostics SL and Ivastatin Therapeutics S (all unrelated to this work). A.C. reports honoraria for lectures from AstraZeneca, Bristol-Myers Squibb, Ferrer, Boehringer Ingelheim, MSD, Novartis, Bristol-Myers Squibb, and AMGEN and to have received consulting fees from Novartis, AstraZeneca, Ferrer, and AMGEN. The remaining authors have nothing to disclose.

MeSH terms

Substances